CN109865128A - A Bilutai is treating and preventing the application in diabetes complicated with cerebral infarction drug - Google Patents
A Bilutai is treating and preventing the application in diabetes complicated with cerebral infarction drug Download PDFInfo
- Publication number
- CN109865128A CN109865128A CN201711262008.5A CN201711262008A CN109865128A CN 109865128 A CN109865128 A CN 109865128A CN 201711262008 A CN201711262008 A CN 201711262008A CN 109865128 A CN109865128 A CN 109865128A
- Authority
- CN
- China
- Prior art keywords
- bilutai
- cerebral infarction
- treating
- preventing
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to the novel medical uses of A Bilutai, that is A Bilutai is treating and preventing the application in diabetes complicated with cerebral infarction drug, A Bilutai is used generally in the form of pharmaceutical composition, this composition contains the calm and peaceful pharmaceutically acceptable auxiliaries of the A Bilu as active constituent of therapeutically effective amount, it is usually administered with subcutaneous routes, main dosage form is injection liquor.The clinical experimental study carried out to the present invention shows, A Bilutai is better than non-diabetic to the curative effect of Diabetes Mellitus and merges Cerebral Infarction Patients, the diabetes performance of patient can not only be effectively relieved in A Bilutai, nervous function can also be improved, to be conducive to the recovery of patient's entirety state of an illness.
Description
Technical field
The present invention relates to field of medicinal chemistry, specifically, the present invention relates to the novel medical use of A Bilutai, i.e. Ah must
Lu Tai is treating and preventing the application in diabetes complicated with cerebral infarction drug.
Background technique
A Bilutai (albiglutide) is to restore a kind of -1 medicine of novel glp-1 of β cell dysfunction as the main purpose
Object has longer drug effect and Half-life in vivo compared with Exenatide and Liraglutide.
Diabetes are one group of metabolic diseases characterized by hyperglycemia.Hyperglycemia be then due to defect of insulin secretion or
Its biological effect is impaired, or both have concurrently and cause.Long-standing hyperglycemia when diabetes, cause various tissues, especially eye,
Kidney, heart, blood vessel, the chronic lesion of nerve, dysfunction.It is a kind of common chronic disease for seriously endangering human health.Currently,
There is nearly 200,000,000 diabetic in the whole world, and nearly half lives in the Asian-Pacific area.Wherein, there are about 50,000,000 diabetics for China.By sugar
Complication caused by urine disease, such as inpairment of vision, low level amputation, heart disease bring great pain to patient and its family members, but big
Some patientss are not but because the reasons such as treatment means backwardness can be effectively controlled blood glucose.
Some researches show that about 10-30% Cerebrovascular Disease Patients suffer from diabetes；And diabetic atherosclerosis
Incidence is 5 times more compared with normal person, and the time occurred is more early than normal person, also more serious.This is because diabetic due to
Hypoinsulinism and cause sugar, fat and protein metabolism disorder, wherein insufficient insulin makes based on carbohydrate metabolism disturbance
The amount that glucose is converted into fat and stores is reduced, and fat is largely decomposed into triglycerides and free fatty acid, and gallbladder consolidates ferment synthesis
It is vigorous, increase blood lipid especially cholesterol, causes the damage of blood vessel, easily formation artery sclerosis；The concurrent cerebral infarction of diabetic
It fills in more than cerebral hemorrhage.Middle Microinfarct is again more than sheet infraction, and with multiple in the majority.
The present inventor has found that A Bilutai has apparent treatment to diabetes complicated with cerebral infarction by clinical research test
And/or prevention effect.
Summary of the invention
It is an object of the present invention to provide A Bilutai to treat and prevent answering in diabetes complicated with cerebral infarction drug
With.
A Bilutai of the invention is treating and preventing the application in diabetes complicated with cerebral infarction drug, and A Bilutai is general
In the form of pharmaceutical composition use, this composition contain therapeutically effective amount the A Bilu as active constituent it is calm and peaceful can medicine
It with auxiliary material, is usually administered with subcutaneous routes, main dosage form is injection liquor.
Heretofore described A Bilutai, which refers to, can pass through business with the mutually isostructural compound of trade name, A Bilutai
Channel purchase.
The curative effect that the clinical experimental study carried out to the present invention shows A Bilutai to Diabetes Mellitus
It is better than non-diabetic and merges Cerebral Infarction Patients, A Bilutai can not only be effectively relieved the diabetes performance of patient, can also change
Kind nervous function, to be conducive to the recovery of patient's entirety state of an illness.
Specific embodiment
With specific embodiment, the invention will be further described below.
Therapeutic effect of 1 A Bilutai of embodiment to Diabetes Mellitus
Experimental subjects and grouping: clinic randomly selects Cerebral Infarction Patients 360 within morbidity 48 hours, wherein treatment group
240, control group 120.All cases select oral hypoglycemic agents according to the state of an illness, control fasting blood-glucose in 6-8mmol/L,
Stabilizing blood pressure is taken, using low dose of dehydrating agent, calcium antagonist (Nimodipine) and platelet suppressant drug (low dose of Ah Si
Woods), anti-infective equal symptomatic treatments.Treatment group: subcutaneous injection A Bilutai injection 30mg, once a day, 28 days are a treatment
Journey；Control group: subcutaneous injection same amount of normal saline, once a day, 28 days as a treatment course.The state of an illness is compared with 2 courses for the treatment of of severe one row.
Analysis project and index: hemorheology index is (whole blood high shear viscosity, whole blood low shear viscosity, Plasma Viscosity, red thin
Born of the same parents' aggregate index and fibrinogen content).
As a result: the comparison of the pretherapy and post-treatment Hemorheology index of two groups of patients is see following table (table 1)
1 two groups of blood stream of patients of table, which become, learns Indexs measure result
Note: compared with before treatment, P < 0.01 *；Compared with the control group#P<0.05
Through χ2Test statistics analysis shows that: the treatment group patient of diabetes complicated with cerebral infarction compared with control group patient,
A Bilutai can more improve hemorheology index well, reduce blood viscosity, be conducive to conditions of patients recovery.
Treatment of 2 A Bilutai of embodiment to diabetes complicated with cerebral infarction
Person patient is randomly divided into two groups according to the random table of computer SPSS Software Create by 80 patients.Treatment group 40
Example, male 21, female 19；Age 57.5-86.5 years old；Neurological deficits score 15-39 points, average (23.1 ± 7.8) point.It is right
According to group 40, male 23, female 17；Age 54.5-85.5 years old；Neurological deficits score l4-38 points, average (22.7 ±
6.6) divide.Two groups of genders, age, neurological deficits score are through statistical analysis, no significant difference (P > 0.05), tool
There is comparativity.Two groups of patients give conventional therapy (OADs, dehydrant and supporting treatment etc.).Treatment group is subcutaneous on this basis
Inject A Bilutai 30mg, once a day, successive administration 28 days；Control group gives the physiological saline of equivalent, once a day, the course for the treatment of
It also is 28 days.
It predominantly detects and analysis indexes: fasting blood-glucose (BS) and glycosylated hemoglobin (HbA1C)
As a result: the pretherapy and post-treatment BS and HbA of two groups of patients1CComparison see following table (table 2).
2 two groups of blood stream of patients of table, which become, learns Indexs measure result
Note: compared with before treatment, P < 0.05 *；Compared with the control group#P<0.05
This result of study shows that A Bilutai can be substantially reduced fasting blood-glucose and saccharification hemoglobin content, to exchange
Section sugar and fat metabolism delay conditions of patients progress to play a significant role.
Claims (4)
1. A Bilutai is treating and preventing the application in diabetes complicated with cerebral infarction drug, which is characterized in that with pharmaceutical composition
The form of object uses, and composition contains the calm and peaceful pharmaceutically acceptable auxiliaries of the A Bilu as active constituent of therapeutically effective amount, with subcutaneous
Injection administration, main dosage form are injection liquor.
2. A Bilutai according to claim 1 is treating and preventing the application in diabetes complicated with cerebral infarction drug,
It is characterized in that, administrated method are as follows: patient selects oral hypoglycemic agents according to the state of an illness, makes fasting blood-glucose control in 6-8mmol/L, takes
Stabilizing blood pressure, using low dose of dehydrating agent, Ah must is subcutaneously injected in calcium antagonist and platelet suppressant drug, anti-infective symptomatic treatment
Shandong Thailand injection 30mg, once a day, 28 days as a treatment course.
3. A Bilutai according to claim 2 is treating and preventing the application in diabetes complicated with cerebral infarction drug,
It is characterized in that, the calcium antagonist is Nimodipine.
4. A Bilutai according to claim 2 is treating and preventing the application in diabetes complicated with cerebral infarction drug,
It is characterized in that, the platelet suppressant drug is low-dosage aspirin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711262008.5A CN109865128A (en) | 2017-12-04 | 2017-12-04 | A Bilutai is treating and preventing the application in diabetes complicated with cerebral infarction drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711262008.5A CN109865128A (en) | 2017-12-04 | 2017-12-04 | A Bilutai is treating and preventing the application in diabetes complicated with cerebral infarction drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109865128A true CN109865128A (en) | 2019-06-11 |
Family
ID=66915732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711262008.5A Pending CN109865128A (en) | 2017-12-04 | 2017-12-04 | A Bilutai is treating and preventing the application in diabetes complicated with cerebral infarction drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109865128A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3981401A1 (en) * | 2020-10-06 | 2022-04-13 | InSphero AG | Pharmaceutical combination for the treatment and/or prevention of diabetes comprising a calcium channel blocking agent and an incretin mimetic |
-
2017
- 2017-12-04 CN CN201711262008.5A patent/CN109865128A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3981401A1 (en) * | 2020-10-06 | 2022-04-13 | InSphero AG | Pharmaceutical combination for the treatment and/or prevention of diabetes comprising a calcium channel blocking agent and an incretin mimetic |
| WO2022074057A1 (en) * | 2020-10-06 | 2022-04-14 | Insphero Ag | Pharmaceutical combination for use in the treatment and/or prevention of diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103108637A (en) | Methods of intravenous administration of glyburide and other drugs | |
| CN105473155A (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| CN105287518A (en) | Pharmaceutical composition overcoming postoperative sleep disorder | |
| Pete et al. | Local anesthetics | |
| CN109865128A (en) | A Bilutai is treating and preventing the application in diabetes complicated with cerebral infarction drug | |
| Chen et al. | Successful rescue of a patient with acute aconitine poisoning complicated by polycystic renal hemorrhage | |
| CN102639128B (en) | Sulfonamides for the prevention of diabetes | |
| JPH01261331A (en) | Drug composition containing fructose-1, 6-diphosphate useful for treatment of acute alcoholism | |
| CN104784192A (en) | Application of clam meat oligosaccharide in preparation of hypoglycemic drugs and preparation method of clam meat oligosaccharide | |
| CA3104476C (en) | Bowel care using iontophoresis | |
| CN107998134A (en) | The beautiful application in the pharmaceutical preparation for preparing auxiliary treatment diabetes can be won | |
| Manto et al. | Hypoglycemia associated with phenytoin intoxication | |
| Baby et al. | Prescribing pattern of antidiabetic drugs for type 2 diabetic in tertiary care teaching hospital | |
| CN101156946A (en) | Application of antihypelipidemic medicine, hydrochloric acid racemic anisodamine, vitamine B**, nerve growth factor in the preparation of combination medicine for treating diabetes | |
| Horvath et al. | The effects of large doses of intravenous insulin in psychotic nondiabetic patients | |
| CN115624543B (en) | Medicine for treating migraine, pharmaceutical composition, preparation method and pharmaceutical application thereof | |
| CN101642561A (en) | New application of exenatide acetate and medicine aiming at new application | |
| RU2457834C1 (en) | Method of treating metabolic syndrome | |
| CN107281408A (en) | A kind of hypoglycemic traditional Chinese medicine composition and preparation method thereof | |
| Ma et al. | Effects of Dexmedetomidine Combined with Sufentanil on P2X7 Receptor Expression in Peripheral Blood Mononuclear Cells in Patients with Burn Pain. | |
| CN105833001B (en) | Purposes of the SHENQI JIANGTANG KELI in diabetic cardiomyopathy medicine is prepared | |
| Gosavi et al. | Comparison of efficacy of ketamine and dexmedetomidine for prevention of pain due to propofol injection | |
| CN104784243B (en) | A kind of application of Chinese medicine composition that can effectively treat frostbite rhagadia in prevention, treatment diabetes | |
| CN103877106A (en) | New use of acarbose | |
| Chen et al. | Effect of Danhong Injection Combined with Magnesium Polarization Solution and Nitrate in Treating Coronary Heart Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190611 |